{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:05:39Z","timestamp":1790870739693,"version":"4.1.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>High levels of circulating tumor cells (CTC) are a powerful predictor of poor outcomes in newly diagnosed multiple myeloma, yet the mechanistic underpinnings of this correlation remain unknown. To investigate whether CTC-related pathobiology is driven by a specific CTC subset, paired bone marrow and blood samples from patients with newly diagnosed multiple myeloma were analyzed by single-cell transcriptomics and whole-genome sequencing. This revealed that down to the individual clone level, CTC and paired bone marrow cells are transcriptionally similar, without evidence for a distinct circulating population. In contrast, bone marrow myeloma cells from patients with high CTC levels had increased proliferation and unbalanced primary genetic events, including enrichment for MAF and CCND translocations. To investigate the impact of heterogenic genomic events on CTC levels, whole-exome and bulk RNA sequencing from the Multiple Myeloma Research Foundation CoMMpass data set were analyzed and validated in our in-house data sets. Bone marrow tumor cells from patients with high CTC levels were uniformly characterized by transcriptomic signatures of proliferation. Furthermore, CTC levels were uniquely dependent on primary genomic events and high-risk secondary genomic events, including amplification 1q, deletion 1p, deletion 13q, biallelic TP53 mutations, and increased apolipoprotein B editing complex\u2013induced mutations even in patients without MAF translocations. Finally, we developed a model that predicts the impact of genetic alterations and tumor burden on CTC levels. In sum, we reveal that CTC are the net result of tumor burden, primary translocations, and secondary genomic events, making CTC a powerful biomarker for genomics-driven high-risk disease in patients with newly diagnosed myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030083","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:37:35Z","timestamp":1766079455000},"page":"932-945","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-0590","authenticated-orcid":false,"given":"Cathelijne","family":"Fokkema","sequence":"first","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3722-9696","authenticated-orcid":false,"given":"Luca","family":"Bertamini","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6145-6154","authenticated-orcid":false,"given":"Madelon M. E.","family":"de Jong","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8616-6607","authenticated-orcid":false,"given":"Sabrin","family":"Tahri","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1296-120X","authenticated-orcid":false,"given":"Davine","family":"Hofste op Bruinink","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Kellermayer","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Papazian","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"den Hollander","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P. W.","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie C. G.","family":"Stoetman","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0283-7069","authenticated-orcid":false,"given":"Gregory","family":"van Beek","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco","family":"Hoogenboezem","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-3763","authenticated-orcid":false,"given":"Vincent H. J.","family":"van der Velden","sequence":"additional","affiliation":[{"name":"2Department of Immunology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"3Hematology Unit, Haut Leveque Hospital, University Hospital Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"4Hematology Department, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"5Hematology Department, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Rowe","sequence":"additional","affiliation":[{"name":"6Johnson & Johnson, High Wycombe, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Vieyra","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[{"name":"6Johnson & Johnson, High Wycombe, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"van Duin","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8575-9213","authenticated-orcid":false,"given":"Mathijs A.","family":"Sanders","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Cupedo","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10192","key":"2026022611213293800_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"2026022611213293800_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"27","key":"2026022611213293800_bib3","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026022611213293800_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","article-title":"More than 2% of circulating tumor plasma cells defines plasma cell leukemia\u2013like multiple myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"J Clin Oncol"},{"issue":"27","key":"2026022611213293800_bib5","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026022611213293800_bib6","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/ajh.27414","article-title":"Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma","volume":"99","author":"Kostopoulos","year":"2024","journal-title":"Am J Hematol"},{"issue":"6","key":"2026022611213293800_bib7","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/cancers12061499","article-title":"Detection of circulating tumor plasma cells in monoclonal gammopathies: methods, pathogenic role, and clinical implications","volume":"12","author":"Sanoja-Flores","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2026022611213293800_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Luzalba","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026022611213293800_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood.V88.1.289.289","article-title":"Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma","volume":"88","author":"Billadeau","year":"1996","journal-title":"Blood"},{"issue":"7","key":"2026022611213293800_bib10","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","article-title":"Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma","volume":"106","author":"Nowakowski","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2026022611213293800_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026022611213293800_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","article-title":"MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology","volume":"13","author":"Dutta","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"2026022611213293800_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","article-title":"Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination","volume":"34","author":"Garc\u00e9s","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"2026022611213293800_bib14","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"issue":"27","key":"2026022611213293800_bib15","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1200\/JCO.21.01217","article-title":"Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile","volume":"40","author":"Hofste Op Bruinink","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026022611213293800_bib16","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"issue":"4","key":"2026022611213293800_bib17","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"issue":"11","key":"2026022611213293800_bib18","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"issue":"6","key":"2026022611213293800_bib19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"issue":"6282","key":"2026022611213293800_bib57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"issue":"3","key":"2026022611213293800_bib58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41587-022-01468-y","article-title":"Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes","volume":"41","author":"Gao","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2026022611213293800_bib20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","article-title":"Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences","volume":"4","author":"Soneson","year":"2015","journal-title":"F1000Res"},{"issue":"12","key":"2026022611213293800_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"14","key":"2026022611213293800_bib22","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2026022611213293800_bib23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41556-021-00766-y","article-title":"Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma","volume":"23","author":"Frede","year":"2021","journal-title":"Nat Cell Biol"},{"key":"2026022611213293800_bib24","doi-asserted-by":"crossref","first-page":"104961","DOI":"10.1016\/j.ebiom.2023.104961","article-title":"CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy","volume":"100","author":"Tang","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"2026022611213293800_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14712598.2020.1677603","article-title":"The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls","volume":"20","author":"Macarulla","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"7237","key":"2026022611213293800_bib26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature07710","article-title":"AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA","volume":"458","author":"Fernandes-Alnemri","year":"2009","journal-title":"Nature"},{"issue":"1","key":"2026022611213293800_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-021-00725-x","article-title":"AIM2 deficiency in B cells ameliorates systemic lupus erythematosus by regulating Blimp-1-Bcl-6 axis-mediated B-cell differentiation","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"353","key":"2026022611213293800_bib28","doi-asserted-by":"crossref","first-page":"353ra113","DOI":"10.1126\/scitranslmed.aad8949","article-title":"Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma","volume":"8","author":"Liu","year":"2016","journal-title":"Sci Transl Med"},{"issue":"16","key":"2026022611213293800_bib29","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1093\/emboj\/17.16.4848","article-title":"The mtDNA-encoded ND6 subunit of mitochondrial NADH dehydrogenase is essential for the assembly of the membrane arm and the respiratory function of the enzyme","volume":"17","author":"Bai","year":"1998","journal-title":"The EMBO J"},{"issue":"21","key":"2026022611213293800_bib30","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1038\/sj.onc.1208536","article-title":"Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells","volume":"24","author":"Mahtouk","year":"2005","journal-title":"Oncogene"},{"issue":"10","key":"2026022611213293800_bib31","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.clml.2019.09.160","article-title":"Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma","volume":"19","author":"Perini","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2026022611213293800_bib32","doi-asserted-by":"crossref","first-page":"e70218","DOI":"10.1002\/hem3.70218","article-title":"Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma","volume":"9","author":"Garces","year":"2025","journal-title":"Hemasphere"},{"issue":"9","key":"2026022611213293800_bib33","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s43018-025-01006-0","article-title":"SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors","volume":"6","author":"Lightbody","year":"2025","journal-title":"Nat Cancer"},{"issue":"4","key":"2026022611213293800_bib34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2004-07-2909","article-title":"The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications","volume":"105","author":"Podar","year":"2005","journal-title":"Blood"},{"key":"2026022611213293800_bib35","first-page":"1561607","article-title":"Long noncoding RNA BCYRN1 recruits BATF to promote TM4SF1 upregulation and enhance HCC cell proliferation and invasion","volume":"2022","author":"Liu","year":"2022","journal-title":"Dis Markers"},{"key":"2026022611213293800_bib36","doi-asserted-by":"crossref","first-page":"8326940","DOI":"10.1155\/2022\/8326940","article-title":"MACC1 promotes the progression and is a novel biomarker for predicting immunotherapy response in colorectal cancer","volume":"2022","author":"Xiong","year":"2022","journal-title":"J Oncol"},{"key":"2026022611213293800_bib37","doi-asserted-by":"crossref","first-page":"1067234","DOI":"10.3389\/fonc.2023.1067234","article-title":"COMMD proteins function and their regulating roles in tumors","volume":"13","author":"You","year":"2023","journal-title":"Front Oncol"},{"key":"2026022611213293800_bib38","doi-asserted-by":"crossref","first-page":"e81184","DOI":"10.7554\/eLife.81184","article-title":"Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling","volume":"12","author":"Farrell","year":"2023","journal-title":"eLife"},{"issue":"7","key":"2026022611213293800_bib39","doi-asserted-by":"crossref","first-page":"103628","DOI":"10.1016\/j.drudis.2023.103628","article-title":"The emerging role of fatty acid binding protein 5 (FABP5) in cancers","volume":"28","author":"George Warren","year":"2023","journal-title":"Drug Discov Today"},{"issue":"6","key":"2026022611213293800_bib40","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1631\/jzus.B0740640","article-title":"Increased fatty acid synthase as a potential therapeutic target in multiple myeloma","volume":"9","author":"Wang","year":"2008","journal-title":"J Zhejiang Univ Sci B"},{"issue":"16","key":"2026022611213293800_bib41","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-14-3294","article-title":"Regulator of chromosome condensation 2 identifies high-risk patients within both major phenotypes of colorectal cancer","volume":"21","author":"Bruun","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2026022611213293800_bib42","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1182\/blood-2004-11-4201","article-title":"Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome","volume":"105","author":"Ladetto","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2026022611213293800_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12859-023-05165-8","article-title":"Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer","volume":"24","author":"Yu","year":"2023","journal-title":"BMC Bioinformatics"},{"key":"2026022611213293800_bib44","doi-asserted-by":"crossref","first-page":"1160342","DOI":"10.3389\/fonc.2023.1160342","article-title":"Identification of aberrantly expressed lncRNAs and ceRNA networks in multiple myeloma: a combined high-throughput sequencing and microarray analysis","volume":"13","author":"Lu","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"2026022611213293800_bib45","first-page":"5009512","article-title":"Comprehensive analysis of RELL2 as a potential biomarker associated with tumor immune infiltrating cells in a pan-cancer analysis","volume":"2022","author":"Musha","year":"2022","journal-title":"Dis Markers"},{"issue":"7","key":"2026022611213293800_bib46","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuill\u00e8me-Toumi","year":"2005","journal-title":"Leukemia"},{"issue":"12","key":"2026022611213293800_bib47","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens","volume":"4","author":"Maura","year":"2023","journal-title":"Nat Cancer"},{"issue":"4","key":"2026022611213293800_bib48","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2026022611213293800_bib49","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"key":"2026022611213293800_bib50","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"11","key":"2026022611213293800_bib51","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026022611213293800_bib52","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2023-186411","article-title":"Biological and clinical significance of undetectable circulating tumor cells (CTCs) in patients (Pts) with multiple myeloma (MM) [abstract]","volume":"142","author":"Garc\u00e9s","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022611213293800_bib53","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1182\/blood-2024-206825","article-title":"Insights into biological mechanisms responsible for egression of circulating tumor plasma cells (CTCs) in multiple myeloma [abstract]","volume":"144","author":"Jelinek","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022611213293800_bib55","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1182\/blood-2023-188538","article-title":"Circulating tumor cells by next generation flow cytometry may be a new prognostic biomarkers among patients with asymptomatic monoclonal gammopathies [abstract]","volume":"142","author":"Kastritis","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2026022611213293800_bib56","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","article-title":"Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma","volume":"28","author":"Termini","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/9\/932\/2504516\/blood_bld-2025-030083-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/9\/932\/2504516\/blood_bld-2025-030083-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:21:43Z","timestamp":1772122903000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/9\/932\/557385\/Circulating-tumor-cells-in-myeloma-are-a-compound"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,2,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030083","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,26]]},"published":{"date-parts":[[2026,2,26]]}}}